ArticleInternational urology and nephrology2026
Cystatin C-creatinine eGFR discordance and all-cause mortality in adults with preserved creatinine-based kidney function: a dual-cohort study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCreatinine-based estimated glomerular filtration rate (eGFRcr) is widely used to assess kidney function. In middle-aged and older adults, however, serum creatinine can be influenced by muscle mass and other non-GFR determinants. We examined whether cystatin C-creatinine eGFR discordance is associated with mortality among adults with preserved creatinine-based kidney function.
methodsWe analyzed the China Health and Retirement Longitudinal Study (CHARLS) as the primary longitudinal cohort and the National Health and Nutrition Examination Survey (NHANES) 1999-2002 as an external population-based cohort. Analyses excluded participants with prevalent major cardiovascular disease and were restricted to adults with eGFRcr ≥ 60 mL/min/1.73 m
resultsThe CHARLS baseline cohort included 7210 participants, the CHARLS dynamic landmark cohort included 4125 participants, and the NHANES mortality analytic cohort included 984 participants. Baseline eGFR discordance was associated with higher all-cause mortality in CHARLS (hazard ratio [HR], 1.627; 95% confidence interval [CI], 1.389-1.907; P < 0.001) and in NHANES (HR, 1.694; 95% CI, 1.385-2.073; P < 0.001). Associations with nonfatal cardiovascular outcomes in CHARLS and heart disease mortality in NHANES were not robust after multivariable adjustment. In the CHARLS dynamic landmark cohort, remitted discordance and persistent discordance were associated with higher post-2015 all-cause mortality. Prediction analyses showed only modest incremental value beyond conventional risk factors.
conclusionAmong adults with preserved creatinine-based kidney function, substantially lower eGFRcys relative to eGFRcr was associated with higher all-cause mortality in two population-based cohorts. These findings suggest that cystatin C-creatinine eGFR discordance may provide additional prognostic information when eGFRcr appears preserved, although its incremental predictive value was modest.
Indexed as
Identifiers
42410266What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.